Open R&D Models

See the following -

Deloitte Report: Open R&D Models Increase Chances for Late-Stage Success

Press Release | Deloitte | June 15, 2015

Today, as thousands of drug makers interact at the 2015 BIO International Convention, Deloitte is releasing a report suggesting that biopharmaceutical companies could have greater success if they collaborate with other organizations – even competitors – as part of an open innovation approach to research and development. The report – "Executing an Open Innovation Model: Cooperation is Key to Competition for Biopharmaceutical Companies" – shows that drugs sourced via open innovation are three times more likely to achieve late-phase clinical success versus those cultivated under an in-house, closed-model approach.

Read More »